期刊文献+

胺碘酮预防心脏手术后心房颤动效果Meta分析 被引量:2

Meta-analysis of Prophylactic Effects of Amiodarone on Post-operative Atrial Fibrillation
下载PDF
导出
摘要 目的:系统性评价胺碘酮预防心脏手术后心房颤动(房颤)的效果。方法:通过中英文电子数据库及手工检索的方式,收集胺碘酮与安慰剂比较预防心脏手术后房颤效果的随机对照临床试验。运用Meta分析法进行统计。结果:14篇文献符合纳入排除标准,应用固定效应模型合并结果,RR为0.66(95%CI:0.58-0.76)。亚組分析显示,胺碘酮首次给药时间和给药方式对房颤的预防作用没有影响。敏感度分析证实了Meta分析结果的稳定性。结论:与安慰剂相比,胺碘酮可以有效地降低心脏手术后房颤的发生率。 Objective: To review whether prophylactic amiodarone has any preventive effects on the incidence of atrial fibrillation(AF) in patients undergoing cardiac surgery. Method: With the help of electronic databases and hand searches, prophylactic effects of post-operative atrial fibrillations with amiodarone compared with placebo were collected to perform some randomized controlled tests and then statistical combinations were conducted with the meta-analysis. Result: A fixed-effect model of meta-analysis was conducted and 15 identified studies were in accordance with the exclusive criterion. The combined relative risk (RR) was 0.66 ( 95% CI:0.58-0.75 ). The subgroup analyses showed that the time of initial administration of amiodarone or the way of the administraions presented no effects on the postoperative atrial fibrillation. The stability of the result was approved by sensitivity analysis. Condusion: Compared with that of the placebo group, the result demonstrated the effectiveness of amiedarone in decreasing the risk of the atrial fibrillation after heart surgery.
出处 《药物流行病学杂志》 CAS 2006年第2期65-68,共4页 Chinese Journal of Pharmacoepidemiology
关键词 胺碘酮 心脏术后 房颤 META分析 Amiodarone Cardiac post-operation Atrial fibrillation Meta-analysis
  • 相关文献

参考文献24

  • 1Maisel WH,Rawn JD,Stevenson WG.Atrial Fibrillation after cardiac surgery[ J ].Ann Intern Med,2001,135 (12):1061-1073
  • 2宋钟娟,奚菁颖,黄荣飞,童如镜,沈杰,王璐华,陈焰.不同剂量胺碘酮治疗老年人心房颤动的临床疗效及安全性[J].中国药师,2003,6(8):506-507. 被引量:5
  • 3Kluger J,White CM.Amiodarone prevents symptomatic atrial fibrillation and reduces the risk of cerebrovascular accidents and ventricular tachycardia after open heart surgery:Results of the atrial fibrillation suppression trial (AFIST)[J].Card Electrophysio Rev,2003,7 (2):165-167
  • 4White CM,Caron MF,Kalus JS,et al.Intravenous plus oral amiodarone,atrial septal pacing,or both strategies to prevent post-cardiothoracic surgery atrial fibrillation:The atrial fibrillation suppression trial Ⅱ (AFIST Ⅱ)[ J ].Circulation,2003,108 (10 SUPPL.):Ⅱ200-Ⅱ206
  • 5Yazigi A,Rahbani P,Zeid HA,et al.Postoperative oral amiodarone as prophylaxis against atrial fibrillation after coronary artery surgery[ J ].J Cardiothorac Vasc Anesth,2002,16(5):603-606
  • 6White CM,Giri S,Tsikouris JP,et al.A comparison of two individual amiodarone regimens to placebo in open heart sur-gery patients[J].Ann Thorac Surg,2002,74(1):69-74
  • 7Giri S,White CM,Dunn AB,et al.Oral amiodarone for prevention of atrial fibrillation after open heart surgery,the Atrial Fibrillation Suppression Trial (AFIST):A randomised placebo-controlled tria[ J ].Lancet,2001,357 (9259):830-836
  • 8Harahsheh BS,Sawalha WA.Effect of amiodarone on atrial fibrillation after coronary artery bypass surgery[ J ].Saudi Med J,2001,22(9):797-799
  • 9Treggiari-Venzi MM,Waeber JL,Perneger TV,et al.Intravenous amiodarone or magnesium sulphate is not cost-beneficial prophylaxis for atrial fibrillation after coronary artery bypass surgery[ J ].Br J Anaesth,2000,85 (5):690-695
  • 10Lee SH,Chang CM,Lu M J,et al.Intravenous amiodarone for prevention of atrial fibrillation after coronary artery bypass grafting[J].Ann Thorac Surg,2000,70(1):157-161

二级参考文献23

  • 1方儒修.乙胺碘呋酮的艰辛历程[J].心血管病学进展,1996,17(4):195-200. 被引量:14
  • 2倪根珊.药物临床应用撷粹[M].北京:八一出版社,1994.275-280.
  • 3Lindgarde F.The effect of Orlistat on body weight and coronary hert disease risk profile in obese patients:the Swedish Muhimorbidity Study.J Intern Med,2000,248(3) :245.
  • 4Hollander PA, Elbein SC, Hirsch IB, et al. Role of Orlistat in the treatment of obese patients with type 2 diabetes. A 1 - year randomized double - blind study. Disbetes Care, 1998,21(8) : 1288.
  • 5Reaven G, Segal K, Hauptman J, et al. Effect of Orlistat - assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol, 2001,87 (7) : 827.
  • 6Kelley DE, Bray GA, Pi - Sunyer FX, et al. Clinical efficacy of Orlistat therapy in overweight and obese patients with insulin- treated type 2 diabetes : a 1 - year randomized controlled trial . Diabetes Care,2002,25(6) : 1033.
  • 7Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebocontrolled trial of Orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.Lancet, 1998,352(9123) : 167.
  • 8Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with Orlistat:a randomized controlled trial.JAMA, 1999,281(3) :235.
  • 9Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long -term treatment of obesity in primary care settings.Arch Fam Med,2000,9(2) : 160.
  • 10Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with Orlistat for obesity. Obes Res, 2000, 8: 49.

共引文献124

同被引文献31

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部